CryoPort, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton Sells 16,344 Shares

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) CEO Jerrell Shelton sold 16,344 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $7.06, for a total value of $115,388.64. Following the transaction, the chief executive officer now owns 912,419 shares in the company, valued at approximately $6,441,678.14. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jerrell Shelton also recently made the following trade(s):

• On Tuesday, June 17th, Jerrell Shelton sold 151,304 shares of CryoPort stock. The stock was sold at an average price of $6.81, for a total value of $1,030,380.24.
• On Wednesday, June 18th, Jerrell Shelton sold 119,281 shares of CryoPort stock. The stock was sold at an average price of $6.81, for a total value of $812,303.61.
• On Friday, June 20th, Jerrell Shelton sold 69,135 shares of CryoPort stock. The shares were sold at an average price of $6.47, for a total value of $447,303.45.

CryoPort Trading Up 1.6%

NASDAQ:CYRX traded up $0.12 during trading hours on Friday, reaching $7.41. 1,888,642 shares of the stock were exchanged, compared to its average volume of 516,477. The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51. The business has a 50-day moving average of $6.36 and a two-hundred day moving average of $6.68. CryoPort, Inc. has a twelve month low of $4.58 and a twelve month high of $9.78. The company has a market capitalization of $371.54 million, a price-to-earnings ratio of -3.17 and a beta of 1.85.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. The company had revenue of $41.04 million for the quarter, compared to analysts' expectations of $56.19 million. On average, equities analysts predict that CryoPort, Inc. will post -0.99 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CYRX. Cadian Capital Management LP lifted its stake in CryoPort by 14.1% during the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company's stock worth $38,332,000 after purchasing an additional 609,021 shares in the last quarter. Millennium Management LLC lifted its stake in CryoPort by 11.0% during the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock worth $32,208,000 after purchasing an additional 409,353 shares in the last quarter. LPL Financial LLC lifted its stake in CryoPort by 1,366.1% during the fourth quarter. LPL Financial LLC now owns 436,766 shares of the company's stock worth $3,398,000 after purchasing an additional 406,976 shares in the last quarter. Norges Bank acquired a new position in CryoPort during the fourth quarter worth $2,711,000. Finally, Silvercrest Asset Management Group LLC lifted its stake in CryoPort by 77.0% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company's stock worth $5,780,000 after purchasing an additional 323,216 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of CryoPort in a report on Thursday, May 8th. Guggenheim reiterated a "buy" rating and issued a $10.00 price objective on shares of CryoPort in a report on Wednesday, April 16th. Morgan Stanley decreased their price objective on CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. UBS Group upped their price objective on CryoPort from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Finally, Roth Mkm reiterated a "buy" rating and issued a $15.00 price objective on shares of CryoPort in a report on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $11.00.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.